Article content
New Brunswick joins British Columbia and Alberta in implementing “switch” policy that changes coverage for specific biologic medicines.
Patients switching from reference biologics to biosimilar versions will continue receiving safe, effective treatment while saving millions of dollars every year.
Sandoz Canada is committed to supporting patients, their healthcare professionals, and the New Brunswick Government with high quality biosimilar medicines and experienced, comprehensive patient support programs.
BOUCHERVILLE, Quebec, April 21, 2021 (GLOBE NEWSWIRE) Sandoz Canada, a leader in generic pharmaceuticals and biosimilars, welcomes the New Brunswick Government introduction of a biosimilars switch policy to expand access to high-quality biologic medicines so that patients can benefit from these treatments.
Hyrimoz
approved for use in all same indications as reference medicine including rheumatology, gastroenterology and dermatology.
Third Sandoz biosimilar approved in Canada in past 11 months expanding its biosimilars portfolio to six and highlighting Sandoz commitment to broadening access to biosimilars.
BOUCHERVILLE, Quebec, Dec. 17, 2020 (GLOBE NEWSWIRE) Sandoz Canada Inc. announced today that Health Canada has authorized Hyrimoz
® (adalimumab injection, reference biologic drug: Humira
®) on November 4, 2020 for marketing in Canada. Hyrimoz
® has been approved for the treatment of the same nine (9) life-threatening or serious debilitating conditions in adults and children as the reference medicine , including the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.